Midgut-Derived Activin Regulates Glucagon-like Action in the Fat Body and Glycemic Control

Highlights
- Enhanced fly AKH action is essential for high-sugar diet-induced hyperglycemia
- Babo signaling directly promotes AKH response in the fat body
- Midgut-derived Actβ signals to the fat body via Babo and modulates AKH action
- Chronic high-sugar diet impairs midgut homeostasis and increases Actβ production

Authors
Wei Song, Daojun Cheng, Shangyu Hong, ..., Michael B. O’Connor, Pavlos Pissios, Norbert Perrimon

Correspondence
rsong@genetics.med.harvard.edu (W.S.), perrimon@receptor.med.harvard.edu (N.P.)

In Brief
Song et al. reveal an insulin-independent mechanism driving hyperglycemia on a high-sugar diet and identify Activin-β as a gut hormone boosting AKH/glucagon signaling in the fly fat body, ultimately perturbing carbohydrate homeostasis. Activin signaling in mouse hepatocytes also increases glucagon-stimulated glucose production, indicating a conserved role in enhancing glucagon response.

Accession Numbers
GSE92350
Midgut-Derived Activin Regulates Glucagon-like Action in the Fat Body and Glycemic Control

Wei Song,1,2,* Daojun Cheng,1,3 Shangyu Hong,4 Benoit Sappe,1 Yanhui Hu,1 Neil Wei,1 Changqi Zhu,5 Michael B. O’Connor,6 Pavlos Pissios,4 and Norbert Perrimon1,2,6,*

1Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
2Howard Hughes Medical Institute, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
3State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, China
4Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
5Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA
6Lead Contact
*Correspondence: rsong@genetics.med.harvard.edu (W.S.), perrimon@receptor.med.harvard.edu (N.P.)

http://dx.doi.org/10.1016/j.cmet.2017.01.002

SUMMARY

While high-caloric diet impairs insulin response to cause hyperglycemia, whether and how counter-regulatory hormones are modulated by high-caloric diet is largely unknown. We find that enhanced response of Drosophila adipokinetic hormone (AKH, the glucagon homolog) in the fat body is essential for hyperglycemia associated with a chronic high-sugar diet. We show that the activin type I receptor Baboon (Babo) autonomously increases AKH signaling without affecting insulin signaling in the fat body via, at least, increase of Akh receptor (AkhR) expression. Further, we demonstrate that Activin-β (Actβ), an activin ligand predominantly produced in the enteroendocrine cells (EEs) of the midgut, is upregulated by chronic high-sugar diet and signals through Babo to promote AKH action in the fat body, leading to hyperglycemia. Importantly, activin signaling in mouse primary hepatocytes also increases glucagon response and glucagon-induced glucose production, indicating a conserved role for activin in enhancing AKH/glucagon signaling and glycemic control.

INTRODUCTION

In both vertebrates and invertebrates, insulin and counter-regulatory hormones have evolved to maintain stable circulating carbohydrate levels in response to nutritional and environmental cues (Haselton and Fridell, 2010; Unger, 1971). Insulin promotes circulating carbohydrate clearance, while counter-regulatory hormones increase carbohydrate release into circulation. However, high-caloric diets can cause an imbalance between insulin and counter-regulatory hormone regulations, resulting in elevated glycemic levels, a condition known as hyperglycemia (Buettnner et al., 2007; Musselman et al., 2011). Much has been learned about how impaired insulin action or insulin resistance contributes to the carbohydrate metabolic dysregulation associated with hyperglycemia (Fröjdö et al., 2009; McNelis and Oleforsky, 2014). By contrast, very little is known about the role of counter-regulatory hormones in glycemic control under caloric overload conditions.

Glucagon, an important insulin counter-regulatory hormone, is secreted from pancreatic α cells during fasting or exercise and promotes glucose production in the liver via glucagon receptor signaling (i.e., GCGR/cAMP/PKA signaling) (Jiang and Zhang, 2003; Unger and Cherrington, 2012). Glucagon action in hepatocytes is abnormally increased in response to a high-caloric diet in obese or diabetic subjects and contributes to glucose intolerance and hyperglycemia (Matsuda et al., 2002; Sheng et al., 2012). Importantly, inhibition of hepatic glucagon signaling using antisense oligonucleotides has been shown to improve glucose tolerance and to restore normal glycemic levels in diet-induced obese or diabetic mice (Liang et al., 2004). A similar effect of glucagon enhancement has also been reported in diabetic patients (Ali and Drucker, 2009). Previous studies have indicated that the inflammatory factor NIK and the endoplasmic reticulum (ER) stress sensor IRE1α are involved in hepatic glucagon signal transduction in obese mice under high-fat diet feeding (Mao et al., 2011; Sheng et al., 2012).

As a homolog of mammalian glucagon, Drosophila adipokinetic hormone (AKH) is a well-established insulin counter-regulatory hormone involved in carbohydrate metabolic homeostasis (Gálková et al., 2015; Kim and Rulifson, 2004; Lee and Park, 2004). Under starvation conditions, AKH is secreted from corpora cardiaca (CC) endocrine cells and promotes nutrient utilization in the fat body, leading to increased glycemic levels in circulation. The prohormone processing and secretion regulations of AKH and glucagon are similar. AKH also activates a G protein-coupled receptor, AkhR, and triggers cAMP/PKA signaling to regulate carbohydrate metabolism in the fat body, which is reminiscent of glucagon signaling (Bharucha et al., 2008; Grönke et al., 2007; Kim and Rulifson, 2004; Lee and Park, 2004; Rhea et al., 2010). Further, similar to the effects of high-fat diet in mammals, subjecting Drosophila to a chronic high-sugar diet has been shown to increase adiposity, impair insulin signaling in the fat body, and cause hyperglycemia in larvae (Musselman et al., 2011). Thus, we reasoned that investigating how AKH...
response is regulated by high-sugar diet would provide novel insights into how carbohydrate imbalance and hyperglycemia develop in response to excess caloric intake.

In this study, we uncover that fat body AKH action is abnormally enhanced in the context of a high-sugar diet, causing hyperglycemia. We further demonstrate that, in response to high-sugar feeding, midgut produces Activin-β (Actβ) to increase AKH response in the fat body via activation of activin type I receptor Baboon (Babo)/dSmad2 signaling and elevation of AkhR expression, thus leading to a hyperglycemic state.

RESULTS

Regulation of Carbohydrate Metabolism by AKH

To characterize the role of AKH at the organismal level, we used RNAi to knockdown AkhR in various metabolic tissues and measured circulating carbohydrate levels. Knockdown of AkhR in the larval fat body, but not in neurons, the midgut, or muscle, led to a significant reduction in circulating levels of both glucose and trehalose, a disaccharide form of glucose that is the major carbohydrate in the fly hemolymph (Figures 1A and 1B; Figures S1A, S1B, S1D, and S1E). Knockdown of AkhR in the adult fat body also led to a significant reduction in glycemic levels, i.e., circulating glucose and trehalose (Figure S3H). AkhR knockdown in the larval fat body dramatically decreased glucose/trehalose storage but increased glycogen storage (Figure S1C), suggesting that AKH signaling in the fly fat body regulates circulating carbohydrate levels via both glycogen breakdown and glucose/trehalose production.

Mammalian studies have shown that glucagon activates PKA, leading to increased phosphorylation of IRE1α and CREB, CRTC2 nuclear translocation, and CREB transcriptional activity (Mao et al., 2011; Wang et al., 2009). To address whether the AKH signal is transduced in a similar manner in Drosophila, we generated a Drosophila S2R+ cultured cell line stably expressing AkhR. The addition of synthetic AKH to the culture media led to
increased phosphorylation—not nuclease activity—of IRE1, the fly ortholog of IRE1α, in a dose- and PKA-dependent manner and promoted nuclear translocation of Crtc, the fly ortholog of CRTC2 (Figures S1F, S1G, and S1J). Consistently, treatment with synthetic AKH of wild-type larval fat bodies also led to an increase in phosphorylation of IRE1 and CREB2, the fly ortholog of CREB. Moreover, knockdown of AkhR potently blocked this AKH-induced increase in p-IRE1 and p-CREB2 levels (Figure 1E; antibody that recognizes p-CREB2 in Figure S1H). We also found that AKH signaling led to an increase in CREB2 transcriptional activity in the fat body (Figure S1I). Altogether, our results indicate that AKH signaling in the fly fat body is analogous to glucagon signaling in the mammalian liver.

**A Chronic High-Sugar Diet Promotes Glycemic Level by Enhancing AKH Action**

An increase in AkhR expression in the larval fat body was previously shown to be associated with chronic high-sugar feeding (Musselman et al., 2013); however, whether AKH directly contributes to high-calorie diet-induced hyperglycemia is not known. To address this question, we fed larvae a chronic high-sugar diet to induce hyperglycemia and monitored AKH signaling. Compared to the larvae fed normal food, larvae fed a high-sugar diet showed an increase in both their response to synthetic AKH stimulation and homeostatic AKH signaling output in the fat body, as evidenced by increased p-IRE1 and p-CREB2 levels (Figure 1F), indicating that a chronic high-sugar diet enhances larval fat body AKH response. Abolishing AKH signaling via disruption of AkhR, as achieved using either a null mutation of AkhR or a fat body-specific RNAi, significantly alleviated both increased AKH signaling and hyperglycemia associated with high-sugar diet (Figures 1C, 1D, and 1F). These data indicate that high-sugar diet-induced hyperglycemia is attributable to increased AKH signaling in the fat body.

Impaired insulin signaling is known to elevate glycemic levels and contribute to high-sugar diet-induced hyperglycemia (Musselman et al., 2011). AkhR knockdown in the fat body is sufficient to restore normal glycemic levels in the context of InR deficiency, which dramatically impairs insulin signaling and leads to elevated glycemic levels (Figures S1K–S1M). Thus, we next asked whether AKH signaling suppresses hyperglycemia by promotion of insulin signaling under a normal diet. However, knockdown of AkhR failed to affect Akt phosphorylation or FoxO target gene expression (4E-BP and InR) (Figures S3E and S3F), two major readouts of insulin signaling (Owusu-Ansah et al., 2013; Song et al., 2010). Thus, fat body AKH signaling does not impinge on insulin signaling to impact glycemic control.

**An AKH-Induced Hyperglycemia Model in Drosophila**

Ectopic Akh overexpression in the fat body using R4-Gal4 (R4 > Akh) results in hyperglycemia (Figure 2A) (Lee and Park, 2004), suggesting that ectopic Akh expression activates AKH signaling in the fat body in an autocrine manner. Consistently, Akh overexpression leads to a dramatic increase in fat body AKH signaling (Figure 2B). Further, fat body-specific knockdown of AKH/glucagon signaling components significantly affected AKH-induced hyperglycemia (Figure 2C).

Little is known about the molecular mechanism by which AKH regulates carbohydrate metabolism. We thus analyzed the fat body transcriptome via RNA sequencing (RNA-seq) and found that ectopic AKH expression led to significant changes in the expression of 702 genes in the fat body, with 364 downregulated and 338 upregulated (Figure 2D; Table S1). Gene Ontology (GO) enrichment analysis of the differentially expressed genes revealed a significant enrichment of genes involved in carbohydrate metabolism, including glucagon and sucrose metabolism, glycolysis and/or gluconeogenesis, and the TCA cycle (Figure S2A). Genes involved in AKH-associated carbohydrate metabolism were further validated by qPCR and genetic analysis (Figures S2C and S2D). Consistent with activation of CREB2, GO analysis revealed that CREB2 target genes were significantly enriched (Figure S2B). Interestingly, the targets of other transcriptional factors than CREB2 were also enriched (Figure S2B), suggesting potential crosstalk between AKH signaling and other pathways. Note that FoxO target genes were not significantly enriched, consistent with our observation that knockdown of AkhR failed to affect insulin/FoxO signaling (Figures S3E and S3F).

**In Vivo RNAi Screen for Regulators of AKH Signaling**

The AKH-induced hyperglycemia model described above allowed us to perform an in vivo RNAi screen to discover physiological regulators of AKH signaling (Figure 2E). Specifically, transgenic RNAi fly stocks targeting 305 kinases and phosphatases—many of which were previously validated (Sopko et al., 2014)—were crossed to R4 > Akh flies, and glycemic levels (glucose + trehalose) of their offspring were measured. We used glycemic levels as the major readout in this screen as we found it to be more reliable and inclusive than monitoring signaling (i.e., p-IRE1, p-CREB2, or CREB transcriptional activity; data not shown). The screen assay is robust, as knockdown of glucagon/AKH signaling components consistently affected glycemic levels (Figure 2C). We normalized glycemic changes to both negative (w-i, 1, 100% hyperglycemia) and positive (AkhR-ir, 0, 0% hyperglycemia) controls using the formula NGRNAi = (RGRNAi – RGAkhR-ir) / (RGw-i – RGAkhR-ir) (NG, normalized glycemic levels; RG, raw glycemic levels) (Figure 2F). A total of 30 candidate genes were identified that significantly affected AKH-induced hyperglycemia (>1.7 or <0.3, hyperglycemic index values of 3.6 and 2.1, respectively) (Table S2). These genes have been previously implicated in various biological processes. (Figure 2G; Table S2). Among the candidates, the mammalian homologs of Pfk and Sik3 have previously been shown to be involved in glucagon signaling (Pilkis et al., 1982; Wang et al., 2011). Consistently, knockdown of Pfk and Sik3 in the Drosophila fat body significantly enhanced AKH-induced hyperglycemia (hyperglycemic index values of 3.6 and 2.1, respectively) (Table S2).

In addition to changes in glycemic levels, knockdown of a few genes also resulted in changes in larval fat body morphology, developmental delay, and/or pupal lethality. However, we did not observe a strong correlation between these effects and glycemic changes (Figure S2E; Table S2). To further assess how these 30 genes regulate AKH action, we measured AKH signaling outputs and annotated potential mechanisms based on their differential effects on p-IRE1 or p-CREB2 levels (Figure 2H; Figures S2F and S2G).

We also performed a small secondary RNAi screen in wild-type larvae and found that knockdown of these candidates
Figure 2. An AKH-Induced Hyperglycemia Model and In Vivo RNAi Screen

(A–D) Glycemic levels (glucose + trehalose) (A; n = 4, 40 larvae), immunoblots (B), and gene expression (D) in fat bodies from R4 > AKH (UAS-Akh/+; R4-Gal4/+; UAS-w-RNAi) third-instar larvae. Glycemic levels of R4 > AKH larvae with knockdown of AKH/glucagon signaling components (C; n = 4, 40 larvae).

(E and F) Schematic (E) and results (F) of the in vivo RNAi screen of kinases and phosphatases in AKH-induced hyperglycemic flies. Glycemic levels in R4 > Akh + w-i (UAS-Akh/+; R4-Gal4/UAS-w-RNAi) and R4 > Akh + AkhR-i (UAS-Akh/+; R4-Gal4/UAS-AkhR-RNAi) were normalized to 1 (100%) and 0, respectively (n = 3, 30 larvae).

(G) Annotation of novel positive gene “hits” identified in the in vivo RNAi screen (>1.7 or <0.3 as cutoffs) for signaling pathways or biological processes. 

(H) 30 hits modulate AKH-induced hyperglycemia via regulation of p-IRE1 or p-CREB2. Data are presented as means ± SEM. *p < 0.05.
consistently affect glycemic levels in the absence of AKH overexpression (Figure S3A).

**Babo Regulates AKH Response and Carbohydrate Metabolism**

RNAi stocks targeting Babo and Punt (Put), which encode types I and II TGF-β receptors, respectively, were among the reagents exerting the greatest suppression of AKH-induced hyperglycemia in the primary RNAi screen (Table S2; Figure 2H). In Drosophila, there are three different type I TGF-β receptors—Thick-Vein (Tkv), Saxophone (Sax), and Babo—and two shared type II receptors—Put and Wishful-thinking (Wit)—which respond to different ligands and activate distinct downstream transcription factors (Brummel et al., 1999; Gesualdi and Haerry, 2007). Unlike our observation with knockdown of Babo, knockdown of the other two type I receptors, Tkv or Sax, failed to affect AKH-induced hyperglycemia (Figure 3A). Consistently, only knockdown of dSmad2 (the transcription factor downstream of Babo), but not Mad (the transcription factor downstream of Tkv/Sax), significantly suppressed AKH-induced hyperglycemia (Figure 3A).

To examine whether Babo signaling directly regulates AKH signaling, we treated larval fat bodies bearing Babo RNAi with synthetic AKH peptides. Interestingly, Babo RNAi potently blocked the AKH-induced increase in p-CREB2 and p-IRE1 (Figure 3C). Suppression of Babo signaling using RNAi in the context of AkhR deficiency in fat body (n = 4, 40 larvae). Data are presented as means ± SEM. *p < 0.05.
FoxO targets \(4E-BP\) insulin signaling, as indicated by p-Akt and expression of sugar diet-induced hyperglycemia (Musselman et al., 2013) (Figures S3 E–S3G). These results indicate that the effects of Babo signaling on glycemic control are independent of insulin/Act\(\beta\) signaling and high-sugar-induced hyperglycemia and enhancement of AKH signaling in the fat body associated with high-sugar diet conditions (Figures S3C and S3D). We further found that overexpression of \(dSmad2\) in the fat body led to a significant increase in \(AkhR\) mRNA levels (Figure S3D). As Babo/dSmad2 signaling regulates sugar metabolism in an \(AkhR\)-dependent manner (Figure 3F), our results collectively indicate that Babo/dSmad2 signaling mediates fat body AKH response via \(AkhR\) transcriptional-regulation.

**Act\(\beta\)/Babo Signaling Modulates AKH Response in the Fat Body**

*Babo* expression is not elevated in the fat body in response to high-sugar diet (Figure S4A). Thus, we examined the role of ligands that activate Babo in modulating AKH action. Two activin ligands, Act\(\beta\) and Daw, regulate Babo/dSMAD2 signaling in *Drosophila* (Gesualdi and Haerry, 2007). To address whether one or both is involved in Babo-mediated AKH signaling, we first assessed the impact of Act\(\beta\) on carbohydrate metabolism via a loss-of-function mutation (Act\(\beta\)ed80) (Zhu et al., 2008) or ubiquitous knockdown (Actin > Act\(\beta\)-i). In both conditions, we observed a decrease in glycemic levels (Figure 4A; Figures S4B–S4D). Reduction of Act\(\beta\) expression led to a decrease in the fat body AKH response and hyperglycemia under high-sugar diet conditions (Figures 4A and 4D). Conversely, ectopic expression of Act\(\beta\) in the larval fat body was sufficient to increase fat body AKH signaling and glycemic levels (Figures 4B and 4D; Figures S4E and S4F). The increase in glycemic levels was potently diminished by knockdown of either *Babo* or *AkhR* expression in the fat body (Figure 4C; Figure S4G). These data indicate that Act\(\beta\) is involved in Babo-mediated AKH response and carbohydrate metabolism in the fat body.

Different Babo isoforms respond to individual ligands and result in diverse physiological outputs (Gesualdi and Haerry, 2007; Jensen et al., 2009). *BaboA* and *BaboB* are highly expressed in the larval fat body as revealed by RNA-seq analysis (Figure 5A). We determined which Babo isoform(s) is required for Act\(\beta\) regulation of AKH action using RNAi targeting distinct

---

**Figure 4. Act\(\beta\) Signals through Babo to Affect AKH Signaling in the Fat Body**

(A) Glycemic levels (glucose + trehalose) in third-instar larvae with systemic Act\(\beta\) knockdown (left, Actin-Gal4/UAS-Act\(\beta\)-RNAi) or knockout (right, act\(\beta\)ed80) or Act\(\beta\)+/− fed a standard or high-sugar diet. (B) and (C) Glycemic levels in CG > Act\(\beta\) (CG-Gal4+/+; UAS-Act\(\beta\)+) larvae (B) or CG > Act\(\beta\) larvae with gene knockdown (CG-Gal4, tub-Gal80+/+; UAS-Act\(\beta\)/UAS-RNAi) (C) \((n = 4, 40\) larvae). (D) Immunoblots in freshly isolated fat bodies of Act\(\beta\)-RNAi further alleviated hyperglycemia and enhancement of AKH signaling in the fat body associated with high-sugar diet (Figures S3B). Babo RNAi further alleviated hyperglycemia and enhancement of AKH signaling in the fat body associated with high-sugar diet (Figures S3B and S3C). Moreover, activation of Babo signaling via overexpression of either active Babo or dSmad2 in the fat body was sufficient to increase AKH signaling and glycemic levels in wild-type larvae (Figures 3D and 3E), indicating that Babo signaling directly enhances the fat body responses to AKH.

To determine whether the impact of Babo signaling on carbohydrate metabolism is dependent on AKH response, we manipulated Babo signaling in AkhR-deficient larval fat bodies. Interestingly, neither *Babo* knockdown nor dSmad2 overexpression affected glycemic levels when *AkhR* was knocked down in the larval fat body (Figure 3F). Similar results were observed in adults (Figure S3H). Taken together, our results suggest that Babo signaling regulates carbohydrate metabolism and glycemic levels via modulation of the fat body response to AKH.

Importantly, knockdown of *Babo* in the fat body failed to affect insulin signaling, as indicated by p-Akt and expression of FoxO targets (4E-BP and InR), or dILP2-induced hypoglycemia (Figures S3E–S3G). These results indicate that the effects of Babo signaling on glycemic control are independent of insulin/Act\(\beta\)/FoxO signaling in larval fat bodies.
isoforms (Awasaki et al., 2011). Strikingly, only knockdown of Baboa, but not Babob or Baboc, in the larval fat body significantly decreased Actb-induced AKH signaling and hyperglycemia (Figures 5B and 5C). Based on the similarity between Actβ and Baboa in neuronal development and growth regulation (Gesualdi and Haerry, 2007; Zhu et al., 2008), our results suggest that Actβ regulates carbohydrate metabolism in the fat body via Baboa. Moreover, knockdown of Baboa also significantly alleviated AKH signaling and hyperglycemia in the AKH-overexpression flies (Figures 5D and 5E). Our results thus demonstrate that Actβ/Baboa signaling modulates AKH activity and glycemic control in Drosophila.

Daw Does Not Enhance AKH Signaling in the Fat Body
The activin ligand Daw was previously shown to activate Babo c signaling and control glycemic levels (Ghosh and O'Connor, 2014; Jensen et al., 2009). Consistently, we observed that systemic knockdown of Daw decreased, whereas overexpression of Daw in the fat body increased, glycemic levels (Figure 5F). However, unlike Actβ, Daw overexpression failed to enhance AKH signaling and AkhR or Babo loss in the fat body had little effect on Daw-associated glycemic changes (Figures 5G and 5H). Thus, Daw is not likely to regulate glycemic levels by increasing AKH action in the fat body.

We further tested the role of Myo, another activin ligand, which is produced by muscles and functions via Babo/MAPK, but not Babo/dSmad2, signaling in the fat body (Demontis et al., 2014). Ectopic expression of Myo in the larval muscle or fat body failed to enhance AKH signaling (data not shown).

Activin Signaling Enhances Glucagon Action in Mouse Hepatocytes
As activin signaling pathways are highly conserved between Drosophila and mammals, we hypothesized that, as in
**Drosophila**, mammalian activin signaling might also regulate liver glucose metabolism via modulation of glucagon response. We tested this using primary cultured mouse hepatocytes. Similar to the increase in AkhR mRNA levels by Act\(\text{I}\)/Bx\(\text{I}\)o in **Drosophila**, stimulation by Activin A led to a significant increase in expression of the “glucagon receptor” (GCGR) in primary hepatocytes (Figure S5A). Activin A further significantly enhanced glucagon signaling, as indicated by increased p-CREB and p-IRE1\(\alpha\) levels, as well as glucagon-induced glucose production in primary hepatocytes (Figures S5B and S5C). Treatment with the glucagon receptor antagonist Cpd1 (Qureshi et al., 2004) potently blocked the effects of Activin A on glucagon-induced glucose production (Figure S5C), demonstrating a glucagon-dependent mechanism. We also noticed an increase in glucose production under Activin A treatment alone (Figure S5C), suggesting potential mechanism(s) independent of glucagon as well.

Next, we examined whether inhibition of activin signaling attenuates hepatic glucagon response by treating with the inhibitor SB 431542 (SB) (Inman et al., 2002). SB led to a significant suppression of activin signaling, as indicated by p-SMAD3, and alleviated Activin A-enhanced glucagon signaling and hepatic glucose production (Figures S5B and S5C). Interestingly, similar results were observed for TGF-\(\beta\). Specifically, we observed that TGF-\(\beta\)1, but not Myostatin (data not shown), significantly increased GCGR expression, glucagon signaling, and glucagon-induced glucose production in primary mouse hepatocytes (Figures S5D–S5F). Taken together, our results indicate that, in mammals, activin signaling regulates hepatic carbohydrate metabolism, at least, via modulation of the glucagon response (Figure S5G).

**Midgut-Derived Act\(\text{I}\) Regulates Fat Body AKH Action and Glycemic Levels**

We next examined the source(s) of Act\(\text{I}\) that regulates AKH action and carbohydrate metabolism in the fat body. Consistent with previous results (Gibbens et al., 2011; Kim and O’Connor, 2014; Ting et al., 2007), we observed Act\(\text{I}\) expression in the larval central nervous system (CNS), neuroendocrine cells, and motor neurons using Act\(\text{I}\)-Gal4-driving GFP expression (Figures S6A and S6C). Strikingly, we also observed Act\(\text{I}\) expression in most enterodendocrine cells (EEs), as indicated with the EE marker Prospero (Pros), in the larval midgut (Figure 6A; Figure S6B). Act\(\text{I}\)-expressing EEs also produce Tachykinin (TK), an abundant gut hormone (Amcheslavsky et al., 2014; Song et al., 2014), in the posterior midgut (Figures 6B and 6C). Act\(\text{I}\) expression in the midgut was confirmed by qPCR and further was found to be upregulated in response to a chronic high-sugar diet (Figure 6D). High-sugar diet also increased Act\(\text{I}\) induction in the motor neurons in the body wall, but not in the brain (Figure 6D). Importantly, overexpression of Act\(\text{I}\) using Act\(\text{I}\)-Gal4 potently enhanced AKH signaling in the fat body and led to hyperglycemia (Figures 6E and 6F), mimicking the impact of a high-sugar diet on Act\(\text{I}\) elevation and carbohydrate metabolic regulation.

To determine which cell types or tissues produce Act\(\text{I}\) to enhance AKH response in the fat body, we used different Gal4 drivers to specifically overexpress Act\(\text{I}\) in EEs (i.e., using Pros-Gal4 or TKg-Gal4) or in motor neurons (2-38-Gal4) (Figure S6C). Surprisingly, Act\(\text{I}\) overexpression in all EEs (Pros-Gal4) or only in TK-expressing EEs (TKg-Gal4) was sufficient to increase AKH signaling in the fat body, as well as glycemic levels (Figures 6E and 6F). Notably, the elevation in glycemia associated with Act\(\text{I}\) overexpression in EEs was significantly diminished by AkhR deficiency (Figure 6G), indicating that the hyperglycemia associated with EE-derived Act\(\text{I}\) is dependent on AKH signaling. By contrast, Act\(\text{I}\) overexpression in motor neurons (2-38-Gal4) failed to enhance fat body AKH signaling (Figures 6H and 6I). We also excluded the effects of neuroendocrine cell-derived Act\(\text{I}\), as neither fat body AKH signaling nor glycemic levels were affected following Act\(\text{I}\) overexpression in neuroendocrine cells (386Y-Gal4 and c929-Gal4) (Figures 6H and 6I; Figure S6C). Therefore, our results indicate that Act\(\text{I}\) production in EEs remotely regulates fat body AKH response and glycemic homeostasis.

**A High-Sugar Diet Leads to an Increase in the Number of Act\(\text{I}\)-Producing EEs**

The **Drosophila** midgut is an important endocrine organ that senses environmental stresses and nutrient availability and produces multiple peptides or hormones that regulate systemic lipid and carbohydrate metabolism (Chng et al., 2014; Li et al., 2016; Song et al., 2014). We next investigated how chronic high-sugar feeding regulates Act\(\text{I}\) expression in the EEs. To determine whether the effects of Act\(\text{I}\) reflect an acute or a chronic condition, third-instar larvae were fed a high-sugar diet for 6 hr, a time sufficient to evoke an acute response. In contrast to chronic feeding, acute feeding of a high-sugar diet failed to elevate midgut Act\(\text{I}\) expression, AKH signaling, or glycemic levels (Figures S6D–S6F). We next asked whether hemocyte infiltration-associated immune and/or inflammatory responses, as suggested by induction of Jak/Stat or NF-\(\kappa\)B signaling (Woodcock et al., 2015), contribute to high-caloric diet-induced Act\(\text{I}\) induction in EEs. However, we failed to observe any changes in hemocyte infiltration (Hml > GFP) in the midgut and did not observe changes in Jak/Stat signaling (Stat-GFP reporter) or NF-\(\kappa\)B signaling (Opt-GFP reporter) in EEs (Figures S7A–S7C), suggesting that immune and/or inflammatory responses do not directly regulate Act\(\text{I}\) expression in EEs.

During this analysis, we did note a striking observation that the number of EEs and the expression of EE marker Pros in the midgut were potently increased by chronic high-sugar feeding (Figures 7A–7C; Figures S7A–S7C). These results indicate that chronic high-sugar feeding perturbs midgut homeostasis and leads to an increase in EE production. Consistently, the number of Act\(\text{I}\)-producing EEs was also significantly increased under chronic high-sugar feeding (Figures 7A and 7B). In contrast, the overall midgut size, as well as the mass of intestinal stem cells (ISCs) and enterocytes (ECs), was significantly decreased (Figures S7D and S7E). The qPCR results also revealed that mRNA levels of the ISC marker esg and EC marker Pdm1 were significantly decreased (Figure S7F).

As starvation causes effects that are similar to what we observe with chronic high-sugar feeding, including suppressed insulin signaling and increased AKH signaling (Figures S7G and S7I), we further examined whether starvation affects EE number and Act\(\text{I}\) expression in the midgut. Third-instar larvae were
Figure 6. Enteroendocrine Cell-Derived Actβ Modulates AKH Action in the Fat Body

(A and B) Expression of Actβ > GFP (green, UAS-srcGFP/+; Actβ-Gal4/+ in EEs, indicated by Pros (A, red) or TK (B, red), in third larval posterior midgut.

(C) Schematic Actβ > GFP expression pattern in larval EEs.

(D) Actβ mRNA levels in different larval tissues under high-sugar diet.

(E and F) Glycemic levels (glucose + trehalose) (E and H) (n = 4, 40 larvae) and fat body immunoblots (F and I) in Actβ-overexpressing larvae. Glycemic levels in AkhR+/+: Pros > Con (AkhR+/AkhR+; Pros-Gal4/+), AkhR+/+/: Pros > Actβ (AkhR+/AkhR+; Pros-Gal4/UAS-Actβ), and AkhR−/−; Pros > Actβ (AkhR−/AkhR−; Pros-Gal4/UAS-Actβ) larvae (G) (n = 4, 40 larvae per group). Data are presented as means ± SEM. *p < 0.05.
cultured for 6 hr on food containing only agar. However, we failed to observe an induction in the number of EEs, Actβ expression in the midgut, or AkhR expression in the fat body (Figures S7G and S7H). These results indicate that Actβ levels are not induced by acute nutrient deprivation.

Finally, we examined whether the increase in EE-derived Actβ is essential for high-sugar diet-induced hyperglycemic levels by knocking down Actβ specifically in EEs. Knockdown of Actβ using the Pros-Gal4 driver caused a dramatic decrease in Actβ mRNA levels in the midgut under chronic high-sugar diet (Figure 7D). Importantly, Actβ knockdown in EEs significantly lowered the increases in both AKH signaling in the fat body and glyceremic levels associated with chronic high-sugar feeding (Figures 7E and 7F). Taken together, our results indicate that chronic high-sugar feeding perturbs homeostasis of EEs and increases Actβ production in the midgut, leading to a non-cell autonomous enhancement of AKH signaling in the fat body and hyperglycemia (Figure 7G).

DISCUSSION

Chronic high-caloric diets have been reported to impair insulin action and elevate glyceremic levels in both vertebrates and invertebrates (Musselman et al., 2011; Pasco and Léopold, 2012; Susini et al., 1979). Using *Drosophila* as a conserved model of metabolic regulation, we demonstrate that enhanced AKH action, which mobilizes energy storage and increases circulating carbohydrate levels as an insulin counter-regulatory hormone, is also essential for high-sugar diet-induced hyperglycemia. We show that chronic high-sugar feeding abnormally augments AKH sensitivity in the fat body, consistent with previous observation of increased AkhR expression in this tissue (Musselman et al., 2013). Importantly, impaired AKH signaling in the fat body due to AkhR deficiency significantly alleviates the hyperglycemia induced by chronic high-sugar feeding or insulin resistance. However, acute high-sugar feeding fails to increase AKH action or glyceremic level, indicating a pathogenic, but not physiological,
enhancement of AKH response in the fat body under chronic high-sugar diet. Altogether, our study identifies an insulin-independent mechanism for diet-associated hyperglycemia.

Identification of Regulators of AKH Signaling
To study how intracellular AKH signaling is enhanced, we performed an in vivo RNAi screen targeting kinases and phosphatases and identified 30 potential novel candidates that modulate AKH signaling and glycemic control. Future studies that aim to elucidate how these candidates regulate AKH action in the fat body in response to a chronic high-sugar diet will offer a more comprehensive understanding of diet-associated hyperglycemic pathogenesis beyond insulin regulation.

In addition to AKH signaling in the fat body as presented here, AKH production or secretion from CC cells may also contribute to diet-associated hyperglycemia. Interestingly, several metabolic regulators, including AMPK and water sensor ppk28, have previously been shown to affect AKH production and/or secretion (Braço et al., 2012; Kim and Neufeld, 2015; Kim and Rulifson, 2004; Waterston et al., 2014). Thus, regulation of AKH production and/or secretion in the context of high-caloric feeding will be another interesting question to address.

Actβ/Baboβ Regulate AKH Response in the Fat Body
Our results demonstrate that Actβ-induced Babo action in the fat body potentiates AKH signaling. Specifically, we found that Babo signaling triggers an increase in dSmad2 transcriptional activity and AkhR expression. Interestingly, in addition to Actβ, Babo also responds to other activin ligands, including Daw and Myo. Among these activin ligands, only Actβ and Daw signal through dSmad2 (Gesualdi and Haerry, 2007). However, several lines of evidence suggest that Actβ and Daw exert different effects on Babo signaling and trigger distinct downstream outputs. First, Daw deficiency results in reduced insulin signaling and hyperglycemia, but fat body overexpression of an active form of Babo fails to restore normal glycemic levels in Daw mutants (Ghosh and O’Connor, 2014). Consistently, our results revealed that Babo deficiency in the fat body fails to affect Daw-induced hypoglycemia (Figure S5H), indicating that Daw regulation of carbohydrate metabolism is independent of fat body Babo signaling. A plausible explanation is that Daw controls dILP2 secretion to modulate systemic insulin effects in a non-cell autonomous manner (Bai et al., 2013; Ghosh and O’Connor, 2014). In contrast, Actβ promotion of AKH signaling is dependent on Babo function in the fat body. Second, Daw preferentially targets Baboβ (Jensen et al., 2009), but the Babo isoform used for Actβ signaling has not previously been reported. In this study, we demonstrate that Actβ modulates AKH signaling and hyperglycemia via Baboβ in the fat body, but not via Baboα or Baboγ. Collectively, we conclude that Actβ/Baboβ regulates AKH signaling in the fat body, whereas Daw/Baboα regulates dILP2 secretion in the CNS, to differentially control carbohydrate homeostasis. Note that we exclude the possibility that Mav, another activin ligand, is relevant to AKH signaling as it has only a slight effect on Babo signaling in vivo (M.B.O., unpublished data). We also exclude another activin ligand, Myo, which signals through Babo/MAPK in the fat body (Demontis et al., 2014), as Myo shows no effects on AKH signaling (unpublished data).

Actβ Produced in Midgut EEs Affects Fat Body AKH Signaling
One of our striking findings is that Actβ produced by midgut EEs affects fat body AKH signaling, implicating a midgut-to-fat-body axis in glycemic control. Actβ has been previously characterized as a neuronal factor and is abundantly expressed in the central and peripheral nervous systems (PNS) to modulate neuronal development and activity (Kim and O’Connor, 2014; Zhu et al., 2008). We demonstrate for the first time that Actβ is abundantly expressed in EEs of the larval midgut. Midgut EEs are key endocrine cells that sense environmental cues, including stresses and dietary nutrients, and secrete gut hormones that modulate the functions of other tissues (Chng et al., 2014; Li et al., 2016; Song et al., 2014). Strikingly, Actβ overexpression in EEs (Pros-Gal4) leads to a dramatic increase in hyperglycemia in a manner dependent on Akh response in the fat body, suggesting inter-organ communication between the midgut and the fat body. Further, using a midgut-specific TkG-Gal4 that targets TK EEs (i.e., about 23% of Actβ-positive EEs), we show that overexpression of Actβ only in a few EEs is sufficient to lead to a significant increase in fat body AKH signaling activity and glycemic levels. These results are consistent with a model in which Actβ production in midgut EEs affects fat body physiology. Finally, knockdown of Actβ in the midgut using RNAi potently alleviates the increased fat body AKH action and hyperglycemia associated with a chronic high-sugar diet, indicating an essential role for midgut Actβ in diet-associated fat body AKH action and carbohydrate metabolism.

We also noticed that Actβ overexpression in neuroendocrine cells (386Y- or c929-Gal4) or in motor neurons (2-38-Gal4) failed to enhance AKH response in the fat body. Possibly, Actβ may function as a regional hormone, as the larval midgut is surrounded by the fat body, which is relatively far from neuroendocrine cells in the brain and motor neurons in the body wall. Alternatively, only mature Actβ hormone that is produced from the midgut through specific post-translational modifications is able to enhance AKH response in the fat body. In support of this model, different processing regulations of the Ast B prohormone in EEs and neurons have been observed in Drosophila (Baggerman et al., 2002; Reither et al., 2011). The release of active mammalian TGF-β is also context-dependent of distinct activation/localization of TGF-β complexes (Annes et al., 2003).

Intriguingly, we found that a chronic high-sugar diet is associated with an increase in EE number. Several signaling pathways have been implicated in ISC proliferation and EE differentiation in the adult midgut (Zeng et al., 2015), in particular JAK/STAT signaling (Lin et al., 2010). Interestingly, we have observed an increase in JAK/STAT signaling in ISCs under chronic high-sugar feeding (data not shown). Further, Upd3, a Jak/Stat ligand, is elevated in both hemocytes (Woodcock et al., 2015) and enterocytes (data not shown) under high-caloric diet. Further studies that elucidate in detail the signaling crosstalk that controls EE generation in the late larval midgut will be required to understand how a chronic high-sugar diet increases EE number and Actβ production.

Relevance to Mammalian Physiology
Maintenance of stable circulating carbohydrate levels via a balance between insulin and counter-regulator hormones,
particularly glucagon, is conserved in mammals and Drosophila. Whereas insulin regulation is well studied, less is known about AKH/glucagon. Here, we demonstrate that AKH action in the Drosophila fat body is highly similar to glucagon action in the mammalian liver with regards to diet-induced hyperglycemia. Interestingly, and reminiscent of AKH regulation in Drosophila, liver glucagon action is aberrantly enhanced in high-fat diet conditions and a reduction of glucagon signaling specifically in the liver improves glucose tolerance in type II diabetic or insulin resistant subjects (Ali and Drucker, 2009; Liang et al., 2004; Matsuda et al., 2002). Moreover, newly characterized physiological regulators of mouse glucagon signaling, including the unfolded protein response (UPR) sensor IRE1α and the inflammatory NF-κB signaling (Mao et al., 2011; Sheng et al., 2012), have been shown to play similar roles in AKH regulation in Drosophila (Figure 2). Thus, our study provides a conserved model of glucagon regulation and will help to comprehensively characterize regulatory networks involved in liver glucagon signaling.

Like the response of Drosophila Babo to Actβ, the mammalian receptors ALK4 and ALK5 respond to the ligands Activin A, TGF-β1, and Myostatin to activate Smad2/3 transcriptional activity (Pauklin and Vallier, 2015; Rebmpagragada et al., 2003). We found that long-term treatment with Activin A or TGF-β1, but not Myostatin, potently enhances glucagon signaling to increase glucagon-induced glucose production in mouse primary hepatocytes. Activin A and TGF-β1 are produced in multiple organs in mammals, including EEs, and regulate growth, liver inflammation (Bogunovic et al., 2007; Krediet et al., 2009; La Rosa et al., 2004). Enhanced glucagon signaling and increased Activin A/TGF-β1 levels have been coincidently observed in obese or diabetic animals (Mao et al., 2011; Sheng et al., 2012; Yadav et al., 2011; Zaragosi et al., 2010). Importantly, mice with a mutation in Inhba, which encodes the inhibitor Iα subunit of Activin A, are lean and show improved glucose tolerance and hyperglycemia (Li et al., 2009). TGF-β1 or Smad3 deficiency also protects mice from diet-induced diabetes (Yadav et al., 2011). These observations are consistent with our proposal that Activin A/TGF-β1 regulates hepatic glucagon action and glucose production to impact glycemic homeostasis. However, consistent with an in vitro study indicating that acute treatment of Activin A alone promotes liver glycogen breakdown and glucose production (Kojima et al., 1995), we also observed a basal induction of glucose production by Activin A alone, suggesting the presence of a glucagon-independent mechanism. Thus, it will be of interest to characterize the nature and role of glucagon-dependent and -independent mechanisms in regulating liver glucose production under different conditions, such as long- or short-term activin ligand treatment.

**EXPERIMENTAL PROCEDURES**

**Drosophila Studies**

Strains and culture methods used in this study are listed in the Supplemental Experimental Procedures.

**High-Sugar Diet and Carbohydrate Measurement**

25% extra sucrose was added into the standard diet to generate the high-sugar diet food. Determination of carbohydrate levels has previously been described (Kwon et al., 2015; Song et al., 2010). Trehalase (E-TREH) and glucose reagent (K-GLUC) were obtained from Megazyme.

**RNA-Seq Transcriptome Analysis**

Ten fat bodies from late third-instar larvae of each genotype were collected for RNA-seq. Details on sample preparation and data analyses are in the Supplemental Experimental Procedures. RNA-seq data were deposited in the Gene Expression Omnibus (GEO: GSE92350).

**Generation of Stable AkhR-Expressing S2R+ Cells**

A full-length AkhR cDNA was generated by RT-PCR using primers 5'-CGCGAATTCGAGGCAAATCCTTGATGCAG and 3'-AGAATCGGCGCCGCTCTCGGCGGATCGGGGAT, verified by DNA sequencing, and inserted into vector pACS-Stable-Puro (Szollosi et al., 2011). Stable cell selection is described in the Supplemental Experimental Procedures.

**Primary Hepatocyte Culture, HGP Assays, and Immunoblots**

Mouse primary hepatocyte preparation and HGP assays have been previously described (Song et al., 2015; Sheng et al., 2012). Immunoblots were performed as previously described (Song et al., 2010).

**qPCR**

Ten fat bodies, ten midguts, ten body walls, or ten brains from late third-instar larvae of each genotype were collected for RNA extraction and qPCR analysis as previously described (Song et al., 2014). Primers are listed in the Supplemental Experimental Procedures.

**Immunostaining**

Immunostainings of S2R+ cells and larval midgut and brain have been previously described (Song et al., 2010, 2014).

**Statistical Analyses**

Data are presented as the mean ± SEM. Student’s t tests were used to compare two groups. p < 0.05 was considered statistically significant.

**ACCESSION NUMBERS**

The accession number for the RNA-seq transcriptome data reported in this paper is GEO: GSE92350.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.cmet.2017.01.002.

**AUTHOR CONTRIBUTIONS**

W.S. conceived the study and designed and performed experiments. D.C. and Y.H. performed RNA-seq and bioinformatics analysis. D.C., B.S., and N.W. performed primary hepatocyte experiments. C.Z. and M.B.O. generated transgenic flies. W.S. and N.P. discussed results and wrote manuscript.

**ACKNOWLEDGMENTS**

We thank the Transgenic RNAi Project (TRIP) and Bloomington Drosophila Stock Center (BDSC) for providing RNAi stocks; Ronald Kühnlein for AkhR stocks; and Richard Binari, Young Kwon, Stephanie Mohr, Richelle Sopko, Ilia Droujinine, Charles Xu, and Xiaochun Ni for comments. This work was supported in part by the American Diabetes Association (1-16-PDF-108) and the Joslin Pilot and Feasibility Program (P30DK03683629). Work in the M.B.O. lab is supported by NIH grant R01 GM095746. Work in the P.P. lab is supported by NIH grant R01 DK083694. Work in the N.P. lab is supported by NIH and HHMI. N.P., is an Investigator of the Howard Hughes Medical Institute.

Received: July 22, 2016

Revised: October 3, 2016

Accepted: January 4, 2017

Published: February 7, 2017
REFERENCES


Rehfeldt, J., Mage, R., and Bennett, M. (2010). The proprotein convertase encoded by amontillado (amon) is required in Drosophila corpora cardiaca endocrine cells producing the glucose regulatory hormone AKH. PLoS Genet. 6, e1000967.


